Novakand Pharma AB (publ) (LARK) — Cash Flow Reinvestment Rate
Novakand Pharma AB (publ) (LARK) has a Cash Flow Reinvestment Rate of 0.00x as of September 2022, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr379.00K. Check Novakand Pharma AB (publ) cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Novakand Pharma AB (publ) Cash Flow Reinvestment Rate (2012–2021)
Historical reinvestment intensity for Novakand Pharma AB (publ) across 3 annual periods. Explore LARK cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Novakand Pharma AB (publ) (2012–2021)
Year-by-year capital reinvestment analysis for Novakand Pharma AB (publ). For live market cap and broader valuation context, see LARK market cap.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 0.01x | Skr147.73K | Skr22.11 Million | Skr147.73K | ▼ -99.6% |
| 2018 | 1.89x | Skr430.20K | Skr227.60K | Skr430.20K | — |
| 2012 | 0.00x | Skr0.00 | Skr59.21K | Skr0.00 | — |